title: Effects of hemagglutinin fusion peptide on poly(ethylene glycol)-mediated fusion of phosphatidylcholine vesicles.
abstract: The effects of hemagglutinin (HA) fusion peptide (X-31) on poly(ethylene glycol)- (PEG-) mediated vesicle fusion in three different vesicle systems have been compared: dioleoylphosphatidylcholine (DOPC) small unilamellar vesicles (SUV) and large unilamellar vesicles (LUV) and palmitoyloleoylphosphatidylcholine (POPC) large unilamellar perturbed vesicles (pert. LUV). POPC LUVs were asymmetrically perturbed by hydrolyzing 2.5% of the outer leaflet lipid with phospholipase A(2) and removing hydrolysis products with BSA. The mixing of vesicle contents showed that these perturbed vesicles fused in the presence of PEG as did DOPC SUV, but unperturbed LUV did not. Fusion peptide had different effects on the fusion of these different types of vesicles: fusion was not induced in the absence of PEG or in unperturbed DOPC LUV even in the presence of PEG. Fusion was enhanced in DOPC SUV at low peptide surface occupancy but hindered at high surface occupancy. Finally, fusion was hindered in proportion to peptide concentration in perturbed POPC LUV. Contents leakage assays demonstrated that the peptide enhanced leakage in all vesicles. The peptide enhanced lipid transfer between both fusogenic and nonfusogenic vesicles. Peptide binding was detected in terms of enhanced tryptophan fluorescence or through transfer of tryptophan excited-state energy to membrane-bound diphenylhexatriene (DPH). The peptide had a higher affinity for vesicles with packing defects (SUV and perturbed LUV). Quasi-elastic light scattering (QELS) indicated that the peptide caused vesicles to aggregate. We conclude that binding of the fusion peptide to vesicle membranes has a significant effect on membrane properties but does not induce fusion. Indeed, the fusion peptide inhibited fusion of perturbed LUV. It can, however, enhance fusion between highly curved membranes that normally fuse when brought into close contact by PEG.
authors.affiliation: Department of Biochemistry and Program in Molecular/Cell Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599-7260, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Haque
authors.forename: A J
authors.initials: AJ
authors.lastname: McCoy
authors.forename: J
authors.initials: J
authors.lastname: Glenn
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: B R
authors.initials: BR
authors.lastname: Lentz
mesh_terms: D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000494:pharmacology*; D008081:Liposomes; D008561:Membrane Fusion / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology*; D010455:Peptides; D010713:Phosphatidylcholines; D011092:Polyethylene Glycols / Q000494:pharmacology*; D014760:Viral Fusion Proteins / Q000494:pharmacology*
chemical_list: D019267:Hemagglutinin Glycoproteins, Influenza Virus; D008081:Liposomes; D010446:Peptide Fragments; D010455:Peptides; D010713:Phosphatidylcholines; D014760:Viral Fusion Proteins; C050632:polypeptide C; D011092:Polyethylene Glycols; C017251:1,2-oleoylphosphatidylcholine; C028694:1-palmitoyl-2-oleoylphosphatidylcholine